$Moderna, Inc.(MRNA)$ $Pfizer(PFE)$ $SELLAS Life Sciences Group Inc.(SLS)$ $Eli Lilly(LLY)$ AbCellera has a major T-cell engager partnership with Jazz Pharmaceuticals targeting gastrointestinal cancers and other solid tumors. The deal includes $84M in committed upfront payments, up to $792M in potential additional payments per program, and up to $2.376 billion across three programs, plus potential royalties.
Amgen's results provide powerful clinical validation for T-cell engagers in solid tumors, although they don't prove anything about AbCellera's specific candidates. Big Pharma is investing billions in this space, and the transformative potential of these therapies is becoming clearer.
Meanwhile, most of the attention on $AbCellera Biologics(ABCL)$ remains focused on ABCL635. The TCE platform and its multibillion-dollar partnership potential are a massive part of the investment thesis that I believe the market continues to underestimate. This is much bigger than one drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
